Drug intelligence / Profile preview

Nermont

Development stage: Unknown
Lead developer: Grand Medical Group
Modality: Small Molecules
Administration: Oral

Overview

Nermont (memantine hydrochloride) is an orally administered, uncompetitive, moderate-affinity N-methyl-D-aspartate (NMDA) receptor antagonist developed and marketed by Grand Medical Group. It is indicated for the treatment of moderate to severe Alzheimer's disease. By binding to and blocking NMDA receptor-operated cation channels, Nermont modulates the effects of pathologically elevated tonic levels of glutamate, which can otherwise lead to excitotoxicity and neuronal dysfunction. This mechanism helps preserve transient physiological activation of the channels by synaptically released glutamate, thereby improving cognitive function, memory, and daily functioning in patients with neurodegenerative dementia.

Brand names: Nermont
Other names: memantinememantine hydrochloridememantinum

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Nermont.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nermont.